Abstract:Background. Tumor microenvironment (TME) is closely related to the progression of glioma and the therapeutic effect of drugs on this cancer. The aim of this study was to develop a signature associated with the tumor immune microenvironment using machine learning. Methods. We downloaded the transcriptomic and clinical data of glioma patients from the Chinese Glioma Genome Atlas (CGGA) databases (mRNAseq_693). The single-sample Gene Set Enrichment Analysis (ssGSEA) database was used to quantify the relative abundance of immune cells. We divided patients into two different infiltration groups via unsupervised clustering analysis of immune cells and then selected differentially expressed genes (DEGs) between the two groups. Survival-related genes were determined using Cox regression analysis. We next randomly divided patients into a training set and a testing set at a ratio of 7 : 3. By integrating the DEGs into least absolute shrinkage and selection operator (LASSO) regression analysis in the training set, we were able to construct a 15-gene signature, which was validated in the testing and total sets. We further validated the signature in the mRNAseq_325 dataset of CGGA. Results. We identified 74 DEGs associated with tumor immune infiltration, 70 of which were significantly associated with overall survival (OS). An immune-related gene signature was established, consisting of 15 key genes: adenosine triphosphate (ATP)-binding cassette subfamily C member 3 (ABCC3), collagen type IV alpha 1 chain (COL4A1), podoplanin (PDPN), annexin A1 (ANXA1), COL4A2, insulin-like growth factor binding protein 2 (IGFBP2), serpin family A member 3 (SERPINA3), CXXC-type zinc finger protein 11 (CXXC11), junctophilin 3 (JPH3), secretogranin III (SCG3), secreted protein acidic and rich in cysteine (SPARC)-related modular calcium-binding protein 1 (SMOC1), Cluster of Differentiation 14 (CD14), COL1A1, S100 calcium-binding protein A4 (S100A4), and transforming growth factor beta 1 (TGF-β1). The OS of patients in the high-risk group was worse than that of patients in the low-risk group. GSEA showed that interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducer and activator of transcription (STAT3) signaling, interferon gamma (IFN-γ) response, angiogenesis, and coagulation were more highly enriched in the high-risk group and that oxidative phosphorylation was more highly enriched in the low-risk group. Conclusion. We constructed a stable gene signature associated with immune infiltration to predict the survival rates of glioma patients.

Proteomics‑based prognostic signature predicts prognosis and immunity in glioma

Comprehensive Analysis of Multi-Omics Data of Recurrent Gliomas Identifies a Recurrence-Related Signature As a Novel Prognostic Marker.

An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature's Identification and Multi-Omics Mechanisms' Exploration

Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma

A lipid metabolism and immune-related gene signature for predicting the prognosis of human gliomas

Construction of a Prognostic Gene Signature Associated with Immune Infiltration in Glioma: A Comprehensive Analysis Based on the CGGA

Development and Verification of the Amino Metabolism-Related and Immune-Associated Prognosis Signature in Gliomas

Prognosis and clinical features analysis of EMT-related signature and tumor Immune microenvironment in glioma

Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform

A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma

Bioinformatic Profiling Identifies an Immune-Related Risk Signature for Glioblastoma.

Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients.

Analysis of the tumor immune environment identifies an immune gene set-based prognostic signature in non-small cell lung cancer

Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma

Identification and Validation of a 17-Gene Signature to Improve the Survival Prediction of Gliomas

Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated with Glioma Prognose.

Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma

Identification of a cellular senescence-related-lncRNA (SRlncRNA) signature to predict the overall survival of glioma patients and the tumor immune microenvironment

Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance

Identification and validation of a novel 9-gene signature of non-specific classification to predict prognosis in glioma patients

Identification of a pyroptosis-related prognosis gene signature and its relationship with an immune microenvironment in gliomas